Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2012

View Archived Issues

Peptide inhibitor nanoparticles reduce beta-amyloid aggregation in preclinical study

NME protects human bone marrow progenitor cells against radiation

Endocyte to file conditional MAAs in E.U. for anticancer therapeutic and imaging agent

Cell>Point receives SPA agreement from FDA for imaging agent

HIV peptide-loaded dendritic cells evaluated in DALIA trial

Alkermes Pharma Ireland withdraws megestrol MAA

Oncothyreon starts phase I ONT-10 cancer vaccine trial

BioFocus, Argenta and AstraZeneca enter new research agreement

Okairos launches NIH-funded phase I/II trial of HCV vaccine

Epizyme achieves preclinical milestone in mixed-lineage leukemia

Phase II program for heart failure to proceed

Threshold Pharmaceuticals treats first patient in multiple myeloma study

Millennium Pharmaceuticals designs novel PI3K and mTOR inhibitors

FDA approves first effervescent osteoporosis drug

New metabotropic glutamate mGlu2 receptor antagonists developed

New apoptosis inducers divulged

Scientists from Varinel discover novel iron chelators

Domain Therapeutics announces new funding for schizophrenia project

Intercell kicks off phase II/III study of vaccine candidate

Foamix product demonstrates efficacy in phase II trial in impetigo

Novel potential hepatitis C therapies identified at Bristol-Myers Squibb

Boehringer Ingelheim patents new bradykinin B1 receptor antagonists

Novel mineralocorticoid receptor antagonists presented by KBP BioSciences

Amgen reports new myostatin-binding antibodies

Shire withdraws BLA for Fabry's disease therapy

First oral contraceptive for heavy menstrual bleeding approved in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...